Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 10,845 matching trials from the live ClinicalTrials.gov search.
Filters: Columbus, Ohio Clear all
Completed No phase listed Observational Accepts healthy volunteers

Nutritional Supplements & Complementary/Alternative Medicine by Prostate & Breast Cancer Patients

NCT01823549
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer
Interventions
questionnaire administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 30, 2026, 5:59 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

NCT05310071
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
130
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 30, 2026, 5:59 PM EDT
Suspended Phase 3 Interventional

High Intensity Focused Ultrasound (HIFU) Ablation System Study

NCT00392106
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
propafenone, flecainide, dofetilide, sotolol, Pulmonary vein ablation, Amiodarone
Drug · Device
Lead sponsor
ProRhythm, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Fullerton, California • Los Angeles, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2008 · Synced Oct 30, 2026, 5:59 PM EDT
Recruiting Early Phase 1 Interventional

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

NCT04655404
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
Larotrectinib, Larotrectinib surgical
Drug · Procedure
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 30, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

NCT02484430
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent Adult Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
14
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 30, 2026, 5:59 PM EDT
Completed Phase 3 Interventional

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

NCT05079919
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Chula Vista, California + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

NCT03980730
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Tucson, Arizona • New Haven, Connecticut • Atlantis, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 30, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

NCT02621892
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
111
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 30, 2026, 5:59 PM EDT
Completed No phase listed Observational

Cardiovascular Patient Outcomes and Research Team Primary PCI Registry

NCT02201264
View directory record Official record
Conditions
ST Elevation Myocardial Infarction
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
6,726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
14
States / cities
Bryan, Ohio • Chardon, Ohio • Columbus, Ohio + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 30, 2026, 5:59 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis

NCT00643799
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celecoxib, Naproxen, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
51
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tempe, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 30, 2026, 5:59 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 5:59 PM EDT
Completed Not applicable Interventional Results available

Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)

NCT02923193
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Shockwave Lithoplasty® Peripheral Lithoplasty System, Medtronic IN.PACT (DCB)
Device · Drug
Lead sponsor
Shockwave Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
40
States / cities
Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 30, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional

S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00053833
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
irinotecan
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
99
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 30, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT02101944
View directory record Official record
Conditions
Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Pelareorep
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Columbus, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 30, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

NCT00762034
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pemetrexed, Paclitaxel, Carboplatin, Bevacizumab
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
67
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Alhambra, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 30, 2026, 5:59 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

NCT03036098
View directory record Official record
Conditions
Urothelial Cancer
Interventions
Nivolumab, Ipilimumab, Gemcitabine, Cisplatin, Carboplatin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
29
States / cities
Anchorage, Alaska • Fresno, California • Santa Rosa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 30, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

NCT01722487
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Chlorambucil
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
65 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Duarte, California • La Jolla, California • Santa Rosa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 30, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer

NCT05304793
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma
Interventions
Best Practice, Cognitive Behavior Therapy, Questionnaire Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 30, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 30, 2026, 5:59 PM EDT
Completed No phase listed Observational

OrganOx Metra® New Enrollment PAS

NCT05526326
View directory record Official record
Conditions
Liver Transplantation
Interventions
Transplant with normothermic machine perfused (NMP) donor liver
Device
Lead sponsor
OrganOx Ltd.
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Maywood, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 30, 2026, 5:59 PM EDT
Active, not recruiting Phase 2 Interventional

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

NCT03493425
View directory record Official record
Conditions
Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7
Interventions
Carboplatin, Cisplatin, Docetaxel, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Questionnaire Administration, Therapeutic Conventional Surgery
Drug · Radiation · Other + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
154
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Palo Alto, California + 111 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Gabapentin For the Control of Hot Flashes in Women With Breast Cancer

NCT00022074
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Depression, Hot Flashes
Interventions
gabapentin, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
Up to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
18
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 30, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Electronic Patient Reporting of Symptoms During Cancer Treatment

NCT03249090
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Patient Self-Reporting of Symptoms, Usual Care Delivery
Other
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
21 Years and older
Enrollment
1,197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
45
States / cities
Grand Junction, Colorado • Lawrenceville, Georgia • Harvey, Illinois + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 30, 2026, 5:59 PM EDT
Terminated No phase listed Observational

A 48 Subject Study Using Non-invasive Multi-Technology Measurements for Early Detection of Ongoing Hemorrhage

NCT04814810
View directory record Official record
Conditions
Occult Bleeding, Hemorrhage, Hemorrhagic Shock
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 30, 2026, 5:59 PM EDT